Lenabasum 5 mg
JBT101-SSc-002
Phase 3 small_molecule terminated
Quick answer
Lenabasum 5 mg for Diffuse Cutaneous Systemic Sclerosis is a Phase 3 program (small_molecule) at Corbus Pharmaceuticals Holdings with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Corbus Pharmaceuticals Holdings
- Indication
- Diffuse Cutaneous Systemic Sclerosis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated